Skip to main content
OpenTrials

Clinical trial condition

Triple Negative Breast Neoplasms

Explore clinical trials studying Triple Negative Breast Neoplasms. Study availability and eligibility vary by location and protocol.

818 public trials 296 recruiting studies
Refine in advanced search Browse all conditions

Triple Negative Breast Neoplasms trial results

Active, Not Recruiting

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

NCT04915755

Conditions
Breast Diseases, Breast Neoplasms, Neoplasms, +5 more
Locations
  • GSK Investigational Site Burbank, California, United States
  • GSK Investigational Site Duarte, California, United States
  • GSK Investigational Site Palo Alto, California, United States
  • GSK Investigational Site San Francisco, California, United States
View all 198 locations
View Trial Details
Active, Not Recruiting

A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

NCT02755272

Conditions
Breast Diseases, Breast Neoplasms, Carcinoma Breast Stage IV, +5 more
Locations
  • Indiana University Indianapolis, Indiana, United States
  • Washington University in St. Louis St Louis, Missouri, United States
  • Montefiore Medical Center The Bronx, New York, United States
  • Duke University Durham, North Carolina, United States
View Trial Details
Active, Not Recruiting

A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors

NCT05888831

Conditions
Advanced Solid Tumors, Breast Diseases, Breast Neoplasms, +13 more
Locations
  • Local Institution - 0021 Los Angeles, California, United States
  • Local Institution - 0007 New Haven, Connecticut, United States
  • Local Institution - 0010 Hackensack, New Jersey, United States
  • Local Institution - 0022 Lake Success, New York, United States
View all 20 locations
View Trial Details
Active, Not Recruiting

Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer

NCT02788981

Conditions
Breast Cancer, Breast Diseases, Breast Neoplasms, +5 more
Locations
  • University of Alabama - Birmingham Birmingham, Alabama, United States
  • University of Chicago Chicago, Illinois, United States
  • Northshore University HealthSystem Evanston, Illinois, United States
  • Fox Chase Cancer Center Philadelphia, Pennsylvania, United States
View Trial Details
Active, Not Recruiting

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

NCT03821935

Conditions
Adenocarcinoma, Advanced Solid Tumors Cancer, Breast Diseases, +28 more
Locations
  • Highlands Oncology Group, PA /ID# 218942 Springdale, Arkansas, United States
  • City of Hope National Medical Center /ID# 265620 Duarte, California, United States
  • City of Hope Orange County Lennar Foundation Cancer Center /ID# 270785 Irvine, California, United States
  • Yale University School of Medicine /ID# 208356 New Haven, Connecticut, United States
View all 64 locations
View Trial Details
Active, Not Recruiting

Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

NCT03562637

Conditions
Breast Diseases, Breast Neoplasms, Neoplasms, +5 more
Locations
  • Moores UCSD Cancer Center La Jolla, California, United States
  • Kaiser Permanente Medical Center San Diego, California, United States
  • UCSF Helen Diller Family Comprehensive Cancer Centre San Francisco, California, United States
  • Miami Cancer Institute Miami, Florida, United States
View all 128 locations
View Trial Details
Active, Not Recruiting

TH1902 in Patients With Advanced Solid Tumors

NCT04706962

Conditions
Adnexal Diseases, Breast Diseases, Breast Neoplasms, +57 more
Locations
  • Karmanos Cancer Institute Detroit, Michigan, United States
  • START Midwest Grand Rapids, Michigan, United States
  • Pennsylvania Cancer Specialists Research Institute Gettysburg, Pennsylvania, United States
  • Mary Crowley Cancer Research Dallas, Texas, United States
View Trial Details

Related conditions